Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
US6987103B2 · kind B2 · utility
5Cited by
0References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 27, 2003 |
| Grant date | Jan 17, 2006 |
| Priority date | — |
| Expiry date | Jan 17, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising: In a preferred embodiment, the animal is a human being.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.